Catalyst4, Inc. purchased $15.3M of MPLT (indirect holdings)
Catalyst4, Inc. purchased 1,209,225 indirectly-held shares of MapLight Therapeutics, Inc. (MPLT) at an average of $12.66 ($10.74–$13.00, $15.31M total) across 4 trades over 2026-07-28 to 2026-07-30.
How this was made
The 30-second read
Why it matters
The disclosure provides a fresh, primary-source datapoint on ownership and potential sentiment, but it does not include new MPLT operational or financial information.
Market read
Traders may treat the filing as a modest bullish sentiment input, but it is unlikely to drive a durable repricing without accompanying MPLT-specific news.
What to watch
The filing notes no pre-arranged 10b5-1 plan, but the trades span multiple days and include a large tranche at $13.00, which can be consistent with liquidity/positioning rather than a new catalyst.
Background
This is an SEC Form 4 insider transaction disclosure: Catalyst4, Inc. (10% owner) bought MPLT shares indirectly via open-market purchases.
Ticker impact
Catalyst4, Inc. reported a Form 4 purchase of 1,209,225 MPLT shares for about $15.3M, increasing holdings to 20,906,689 shares.
Near-term impact likely limited; any effect is sentiment-driven and may fade without follow-on company-specific news.
The filing is primary-source and sizable, but it does not disclose new MPLT fundamentals, only ownership activity under a Form 4.
Market effects
No direct sector read-through; this is company-specific ownership activity in a biotech/therapeutics name.
None indicated.
None indicated.
Counterpoint
Buying under an indirect 10% owner role may reflect portfolio rebalancing or pre-existing arrangements, so it may not indicate a new view on MPLT fundamentals.
Key entities
- issuerMapLight Therapeutics, Inc.
The company whose shares were purchased, disclosed in the Form 4 as MPLT.
- 10% ownerCatalyst4, Inc.
Reporter of the Form 4, executing indirect open-market purchases totaling about $15.3M.
